Skip to main content

Table 1 Comparision of characteristics of the patients between SIB-IMRT and conventional IMRT

From: Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study

Characteristics SIB-IMRT group (n = 128) Conventional IMRT group (n = 298) P value
Age (years)    0.934
 ≤ 70 110 (85.9%) 257 (86.2%)  
 > 70 18 (14.1%) 41 (13.8%)  
Gender    0.76
 Male 101 (78.9%) 239 (80.2%)  
 Female 27 (21.1%) 59 (19.8%)  
KPS    0.213
 ≥ 80 124 (96.9%) 280 (94%)  
 < 80 4 (3.1%) 18 (6%)  
Smoking    0.214
 No 37 (28.9%) 68 (22.8%)  
 Yes 91 (71.1%) 230 (77.2%)  
PET staging    0.486
 Yes 47 (36.7%) 99 (33.2%)  
 No 81 (63.3%) 199 (66.8%)  
Pathology    0.251
 SCC 74 (57.8%) 190 (63.8%)  
 ADE 47 (36.7%) 86 (28.9%)  
 NSCLC 7 (5.5%) 22 (7.4%)  
TNM stage    0.002*
 IIIA 39 (30.5%) 140 (47%)  
 IIIB 89 (69.5%) 158 (53%)  
T stage    0.009*
 T1 11 (8.6%) 10 (3.4%)  
 T2 50 (39.1%) 86 (28.9%)  
 T3 31 (24.2%) 100 (33.6%)  
 T4 36 (28.1%) 102 (34.2%)  
N stage    0.001*
 N0 1 (0.8%) 14 (4.7%)  
 N1 6 (4.7%) 33 (11.1%)  
 N2 48 (37.5%) 147 (49.3%)  
 N3 73 (57%) 104 (34.9%)  
Treatment modality    0.874
 RT alone 11 (8.6%) 28 (9.4%)  
 Sequential CRT 59 (46.1%) 141 (47.3%)  
 Concurrent CRT 58 (45.3%) 129 (43.3%)  
Prescribed dose (Gy)    0.775
  ≥ 66 11 (8.6%) 18 (6%)  
 59–66 98 (76.6%) 237 (79.5%)  
 55–59 12 (9.4%) 25 (8.4%)  
 50–55 7 (5.5%) 18 (6%)  
PTV volume (ml) 504 (128–960) 402 (51–890) < 0.001*
PTV/lung volume ratio 0.18 (0.04–0.43) 0.12 (0.01–0.32) < 0.001*
  1. KPS Karnofsky performance score, PET Positron emission tomography, TNM Tumor-node-metastasis, SCC Squamous cell carcinoma, ADE Adenocarcinoma, RT Radiotherapy, CRT Chemoradiotherapy, PTV Planning target volume
  2. *p<0.05 was considered significant